Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting (Tables)

v3.19.1
Segment Reporting (Tables)
 9 Months Ended
Mar. 31, 2019
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block] hese segments are components of the Company about which separate financial information is available and regularly evaluated by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Please note that certain totals may not sum due to rounding.
 
Three Months Ended March 31, 2019 (in thousands)
 
iBio, Inc.
 
 
iBio CDMO
 
 
Eliminations
 
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues – external customers
 
$
527
 
 
$
-
 
 
$
-
 
 
$
527
 
Revenues – intersegment
 
 
389
 
 
 
463
 
 
 
(852
)
 
 
-
 
Research and development
 
 
1,053
 
 
 
883
 
 
 
(483
)
 
 
1,453
 
General and administrative
 
 
873
 
 
 
2,340
 
 
 
(369
)
 
 
2,844
 
Operating loss
 
 
(1,010
)
 
 
(2,760
)
 
 
-
 
 
 
(3,770
)
Interest expense
 
 
-
 
 
 
(474
)
 
 
-
 
 
 
(474
)
Interest and other income
 
 
17
 
 
 
3
 
 
 
-
 
 
 
20
 
Consolidated net loss
 
 
(993
)
 
 
(3,231
)
 
 
-
 
 
 
(4,224
)
Total assets
 
 
39,713
 
 
 
9,572
 
 
 
(13,611
)
 
 
35,674
 
Fixed assets, net
 
 
3
 
 
 
24,638
 
 
 
-
 
 
 
24,641
 
Intangible assets, net
 
 
1,423
 
 
 
-
 
 
 
-
 
 
 
1,423
 
Depreciation expense
 
 
1
 
 
 
340
 
 
 
-
 
 
 
341
 
Amortization of intangible assets
 
 
92
 
 
 
-
 
 
 
-
 
 
 
92
 
 
Three Months Ended March 31, 2018 (in thousands)
 
iBio, Inc.
 
 
iBio CDMO
 
 
Eliminations
 
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues – external customers
 
$
78
 
 
$
-
 
 
$
-
 
 
$
78
 
Revenues – intersegment
 
 
323
 
 
 
16
 
 
 
(339
)
 
 
-
 
Research and development
 
 
576
 
 
 
483
 
 
 
(93
)
 
 
966
 
General and administrative
 
 
966
 
 
 
1,885
 
 
 
(246
)
 
 
2,605
 
Operating loss
 
 
(1,141
)
 
 
(2,352
)
 
 
-
 
 
 
(3,493
)
Interest expense
 
 
-
 
 
 
(478
)
 
 
-
 
 
 
(478
)
Interest and other income
 
 
7
 
 
 
1
 
 
 
-
 
 
 
8
 
Consolidated net loss
 
 
(1,134
)
 
 
(2,829
)
 
 
-
 
 
 
(3,963
)
Total assets
 
 
21,920
 
 
 
21,763
 
 
 
(12,649
)
 
 
31,034
 
Fixed assets, net
 
 
6
 
 
 
25,329
 
 
 
-
 
 
 
25,335
 
Intangible assets, net
 
 
1,687
 
 
 
-
 
 
 
-
 
 
 
1,687
 
Depreciation expense
 
 
1
 
 
 
340
 
 
 
-
 
 
 
341
 
Amortization of intangible assets
 
 
86
 
 
 
-
 
 
 
-
 
 
 
86
 
 
Nine Months Ended March 31, 2019 (in thousands)
 
iBio, Inc.
 
 
iBio CDMO
 
 
Eliminations
 
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues – external customers
 
$
1,223
 
 
$
-
 
 
$
-
 
 
$
1,223
 
Revenues – intersegment
 
 
1,153
 
 
 
1,216
 
 
 
(2,369
)
 
 
-
 
Research and development
 
 
3,152
 
 
 
2,005
 
 
 
(1,307
)
 
 
3,850
 
General and administrative
 
 
3,090
 
 
 
7,091
 
 
 
(1,073
)
 
 
9,108
 
Operating loss
 
 
(3,866
)
 
 
(7,880
)
 
 
-
 
 
 
(11,735
)
Interest expense
 
 
-
 
 
 
(1,426
)
 
 
-
 
 
 
(1,426
)
Interest and other income
 
 
57
 
 
 
11
 
 
 
-
 
 
 
68
 
Consolidated net loss
 
 
(3,809
)
 
 
(9,296
)
 
 
-
 
 
 
(13,093
)
Total assets
 
 
39,713
 
 
 
9,572
 
 
 
(13,611
)
 
 
35,674
 
Fixed assets, net
 
 
3
 
 
 
24,638
 
 
 
-
 
 
 
24,641
 
Intangible assets, net
 
 
1,423
 
 
 
-
 
 
 
-
 
 
 
1,423
 
Depreciation expense
 
 
2
 
 
 
1,063
 
 
 
-
 
 
 
1,065
 
Amortization of intangible assets
 
 
243
 
 
 
-
 
 
 
-
 
 
 
243
 
  
Nine Months Ended March 31, 2018 (in thousands)
 
iBio, Inc.
 
 
iBio CDMO
 
 
Eliminations
 
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues - external customers
 
$
316
 
 
$
37
 
 
$
-
 
 
$
353
 
Revenues – intersegment
 
 
954
 
 
 
322
 
 
 
(1,276
)
 
 
-
 
Research and development
 
 
1,870
 
 
 
1,449
 
 
 
(375
)
 
 
2,944
 
General and administrative
 
 
3,286
 
 
 
5,305
 
 
 
(901
)
 
 
7,690
 
Operating loss
 
 
(3,886
)
 
 
(6,395
)
 
 
-
 
 
 
(10,281
)
Interest expense
 
 
-
 
 
 
(1,437
)
 
 
-
 
 
 
(1,437
)
Interest and other income
 
 
23
 
 
 
5
 
 
 
-
 
 
 
28
 
Consolidated net loss
 
 
(3,863
)
 
 
(7,827
)
 
 
-
 
 
 
(11,690
)
Total assets
 
 
21,920
 
 
 
21,763
 
 
 
(12,649
)
 
 
31,034
 
Fixed assets, net
 
 
6
 
 
 
25,329
 
 
 
-
 
 
 
25,355
 
Intangible assets, net
 
 
1,687
 
 
 
-
 
 
 
-
 
 
 
1,687
 
Depreciation expense
 
 
2
 
 
 
1,018
 
 
 
-
 
 
 
1,020
 
Amortization of intangible assets
 
 
256
 
 
 
-
 
 
 
-
 
 
 
256